Efficacy of memantine in the treatment of fibromyalgia: A double-blind, randomised, controlled trial with 6-month follow-up

Pain

Volumn 155, Issue 12, 2014, Pages 2517-2525

  Olivan Blázquez, Bárbara ^a,b   Herrera Mercadal, Paola ^b   Puebla Guedea, Marta ^b   Pérez Yus, Mari Cruz ^b   Andrés, Eva ^c   Fayed, Nicolas ^d   López Del Hoyo, Yolanda ^a,b   Magallon, Rosa ^b,e   Roca, Miquel ^b,f   Garcia Campayo, Javier ^c,g  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d HOSPITAL QUIRÓN   (Spain)

^e Aragon Health Services   (Spain)

^f UNIVERSITAT DE LES ILLES BALEARS   (Spain)

^g HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

Chronic pain; Fibromyalgia; Memantine; Randomised controlled trial

Indexed keywords

MEMANTINE; PLACEBO; AMINO ACID RECEPTOR BLOCKING AGENT;

ADULT; ANALGESIA; ANXIETY; ARTICLE; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERANCE; FEMALE; FIBROMYALGIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SPHYGMOMANOMETER; VISUAL ANALOG SCALE; CLINICAL TRIAL; COGNITION DISORDERS; COMPLICATION; DRUG EFFECTS; FOLLOW UP; MIDDLE AGED; MOOD DISORDERS; MULTICENTER STUDY; NEUROPSYCHOLOGICAL TEST; PAIN MEASUREMENT; PAIN THRESHOLD; PSYCHOLOGICAL RATING SCALE; QUESTIONNAIRE; TREATMENT OUTCOME;

ADULT; COGNITION DISORDERS; DOUBLE-BLIND METHOD; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; FIBROMYALGIA; FOLLOW-UP STUDIES; HUMANS; MALE; MEMANTINE; MIDDLE AGED; MOOD DISORDERS; NEUROPSYCHOLOGICAL TESTS; PAIN MEASUREMENT; PAIN THRESHOLD; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84922738740     PISSN: 03043959     EISSN: 18726623     Source Type: Journal    
DOI: 10.1016/j.pain.2014.09.004     Document Type: Article

References (42)

1. Badía X, Roset M, Herdman M, Segura A. La versión española del EuroQol: descripción y aplicaciones. Med Clin (Barc) 1999;112:79-86.
2. Branco JC, Bannwarth B, Failde I, Abello Carbonell J, Blotman F, Spaeth M, Saraiva F, Nacci F, Thomas E, Caubère JP, Le Lay K, Taieb C, Matucci-Cerinic M. Prevalence of fibromyalgia: a survey in five European countries. Semin Arthritis Rheum 2010;39:448-53.
3. Briley M. Drugs to treat fibromyalgia: the transatlantic difference. Curr Opin Invest Drugs 2010;11:16-8.
4. Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA 2013;309:814-22.
5. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. New York: Academic Press; 1988.
6. Choi DW, Koh JY, Petres S. Pharmacology of glutamate neurotoxicity in cortical cell culture: attenuation by NMDA antagonists. J Neurosci 1988;8:185-96.
7. ® 2009;146:238-44.
8. Fayed N, Garcia-Campayo J, Magallón R, Andrés-Bergareche H, Luciano JV, Andres E, Beltrán J. Localized 1H-NMR spectroscopy in patients with fibromyalgia: a controlled study of changes in cerebral glutamate/glutamine, inositol, choline, and N-acetylaspartate. Arthritis Res Ther 2010;12:R134.
9. Gamero Ruiz F, Gabriel Sánchez R, Carbonell Abelló J, Tornero Molina J, Sanchez-Magro I. Pain in Spanish rheumatology outpatient offices: EPIDOR epidemiological study. Rev Clin Esp 2005;205:157-63.
10. Garcia Campayo J, Magdalena J, Fernández E, Magallón R, Salas M, Sobradiel N. Effectiveness of treatments for fibromyalgia depending of level of care: a meta-analysis. Arthritis Res Ther 2008;10:R81.
11. García-Campayo J, Sanz-Carrillo C. Topiramate as a treatment for pain in multisomatoform disorder patients: an open trial. Gen Hosp Psychiatry 2002;24:417-21.
12. Ghaleiha A, Entezari N, Modabbernia A, Najand B, Askari N, Tabrizi M, Ashrafi M, Hajiaghaee R, Akhondzadeh S. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. J Psychiatr Res 2013;47:175-80.
13. Grant JE, Odlaug BL, Schreiber LR, Chamberlain SR, Won Kim S. Memantine reduces stealing behavior and impulsivity in kleptomania: a pilot study. Int Clin Psychopharmacol 2013;28:106-11.
14. Guy W. Clinical Global Impressions (CGI) scale. In: Rush J, First MB, Blacker D, editors. Psychiatric measures. Washington, DC: American Psychiatric Association; 2000.
15. Harris RE. Elevated excitatory neurotransmitter levels in the fibromyalgia brain. Arthritis Res Ther 2010;12:141.
16. Harris RE, Sundgren PC, Craig AD, Kirshenbaum E, Sen A, Napadow V, Clauw DJ. Elevated insular glutamate in fibromyalgia is associated with experimental pain. Arthritis Rheum 2009;60:3146-52.
17. Johnson JW, Kotermanski SE. Mechanism of action of memantine. Curr Opin Pharmacol 2006;6:61-7.
18. Jones RW. A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors. Int J Geriatr Psychiatry 2010;25:547-53.
19. Kishi T, Iwata N. NMDA receptor antagonists interventions in schizophrenia: meta-analysis of randomized, placebo-controlled trials. J Psychiatr Res 2013;47:1143-95.
20. Koukopoulos A, Serra G, Koukopoulos AE, Reginaldi D, Serra G. The sustained mood-stabilizing effect of memantine in the management of treatment resistant bipolar disorders: findings from a 12-month naturalistic trial. J Affect Disord 2012;136:163-6.
21. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988;318:1728-33.
22. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987;334:1-100.
23. Lobo A, Saz P, Marcos G, Día JL, De La Cámara C, Ventura T, Morales Asín F, Fernando Pascual L, Montañés JA, Aznar S. Revalidation and standardization of the cognition mini-exam (first Spanish version of the Mini-Mental Status Examination) in the general geriatric population. Med Clin (Barc) 1999;112:767-74.
24. ® 2003;103:277-83.
25. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c869.
26. Morel V, Etienne M, Wattiez AS, Dupuis A, Privat AM, Chalus M, Eschalier A, Daulhac L, Pickering G. Memantine, a promising drug for the prevention of neuropathic pain in rat. Eur J Pharmacol 2013;721:382-90.
27. Muayqil T, Camicioli R. Systematic review and meta-analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer's disease and other dementias. Dement Geriatr Cogn Disord Extra 2012;2:546-72.
28. Nikolajsen L, Gottrup H, Kristensen AGD, Jensen TS. Memantine (a N-methyl-D-aspartate receptor antagonist) in the treatment of neuropathic pain after amputation or surgery: a randomized, double-blinded, cross-over study. Anesth Analg 2000;91:960-6.
29. Nüesch E, Häuser W, Bernardy K, Barth J, Jüni P. Comparative efficacy of pharmacological and non-pharmacological interventions in fibromyalgia syndrome: network meta-analysis. Ann Rheum Dis 2013;72:955-62.
30. Olivan-Blázquez B, Puebla M, Masluk B, Pérez-Yus MC, Arcega R, Andrés E, López-Del-Hoyo Y, Magallon R, Roca M, Garcia-Campayo J. Evaluation of the efficacy of memantine in the treatment of fibromyalgia: study protocol for a doubled-blind randomized controlled trial with six-month follow-up. Trials 2013;14:3.
31. Owen RT. Glutamatergic approaches in major depressive disorder: focus on ketamine, memantine and riluzole. Drugs Today (Barc) 2012;48:469-78.
32. Recla JM, Sarantopoulos CD. Combined use of pregabalin and memantine in fibromyalgia syndrome treatment: a novel analgesic and neuroprotective strategy? Med Hypotheses 2009;73:177-83.
33. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-41.
34. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Möbius HJ. A 24-week open-label extension of memantine in moderate to severe Alzheimer's disease. Arch Neurol 2006;63:49-54.
35. Rivera J, Gonzalez T. The Fibromyalgia Impact Questionnaire: a validated Spanish version to assess the health status in women with fibromyalgia. Clin Exp Rheumatol 2004;22:554-60.
36. Sinis N, Birbaumer N, Gustin S, Schwarz A, Bredanger S, Becker ST, Unertl K, Schaller HE, Haerle M. Memantine treatment of complex regional pain syndrome: a preliminary report of six cases. Clin J Pain 2007;23:237-43.
37. Sriwatanakul K, Kelvie W, Lasagna L. Studies with different types of visual analogue scales for measurement of pain. Clin Pharmacol Ther 1983;34:234-9.
38. Suhr JA. Neuropsychological impairment in fibromyalgia: relation to depression, fatigue, and pain. J Psychosom Res 2003;55:321-9.
39. Tejero A, Guimerá EM, Farré JM, Peri JM. Uso clínico del HAD (Hospital Anxiety and Depression Scale) en población psiquiátrica: un estudio de su sensibilidad, fiabilidad y validez. Rev Dep Psiquiatr Fac Med Barc 1986;13:233-8.
40. Valdés M, Collado A, Bargalló N, Vázquez M, Rami L, Gómez E, Salamero M. Increased glutamate/glutamine compounds in the brains of patients with fibromyalgia: a magnetic resonance spectroscopy study. Arthritis Rheum 2010;62:1829-36.
41. Vargas A, Vargas A, Hernández-Paz R, Sánchez-Huerta JM, Romero-Ramírez R, Amezcua-Guerra L, Kooh M, Nava A, Pineda C, Rodríguez-Leal G, Martínez-Lavín M. Sphygmomanometry-evoked allodynia-as imple bedside test indicative of fibromyalgia: a multicenter developmental study. J Clin Rheumatol 2006;12:272-4.
42. Wolfe F, Smythe HA, Yunus MB, Bennet RM, Bombardier C, Goldenberg ADL. American College of Rheumatology 1990. Criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72.